An official website of the European UnionAn official EU website
The Wayback Machine - https://web.archive.org/web/20210223152028/https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-vaccines-covid-19-research-development
COVID-19

Treatments and vaccines for COVID-19: research and development

The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments and vaccines to enable promising medicines to reach patients in the European Union (EU) as soon as possible.

EMA is providing guidance to assist developers of potential COVID-19 medicines to prepare for eventual applications for marketing authorisation

This includes scientific advice and as informal consultation with the COVID-19 EMA pandemic Task Force (COVID-ETF).

The outcome of any consultation or advice from EMA is not binding on developers.

COVID-19 medicines that have received EMA advice

 
Last updated 31 January 2021.

This information should not be read as an endorsement of any medicine.

Ongoing clinical trials in the EU

Information on ongoing COVID-19 clinical trials in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):

Users can find information on:

Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.

For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see Clinical trials in human medicines.

Global cooperation

Medicine regulatory authorities worldwide are also cooperating under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA) to expedite and streamline the development of COVID-19 vaccines and treatments.

For more information, see ICMRA: Cooperation to support the development of COVID-19 vaccines and treatments.

Topics

How useful was this page?

Add your rating
Average